Summit Therapeutics Ownership | Who Owns Summit Therapeutics?

Overview ForecastFinancials Chart Transcripts

Summit Therapeutics Ownership Summary

Summit Therapeutics is owned by 11.62% institutional investors, 84.36% insiders, and 4.01% retail investors. Baker bros. advisors lp is the largest institutional shareholder, holding 3.31% of SMMT shares. SPDR® S&P Biotech ETF is the top mutual fund, with 0.48% of its assets in Summit Therapeutics shares.

SMMT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Summit Therapeutics	11.62%	84.36%	4.01%
Sector	Healthcare Stocks	88.01%	8.90%	3.09%
Industry	Biotech Stocks	109.70%	8.77%	-18.47%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Baker bros. advisors lp	23.22M	3.31%	$181.13M
Vanguard group	8.82M	1.26%	$68.78M
Blackrock	7.90M	1.13%	$61.61M
Fmr	7.57M	1.08%	$59.01M
State street	4.12M	0.59%	$32.16M
Geode capital management	2.96M	0.42%	$23.12M
Price t rowe associates inc /md/	2.04M	0.29%	$15.93M
Millennium management	1.94M	0.28%	$15.15M
Abrdn	1.29M	0.18%	$23.03M
Balyasny asset management	1.01M	0.14%	$7.88M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Baker bros. advisors lp	23.22M	2.31%	$181.13M
Wealth management partners	97.38K	0.75%	$1.74M
Jgp global gestao de recursos ltda.	17.08K	0.69%	$304.79M
Qvt financial lp	575.71K	0.42%	$4.49M
Griffin asset management	110.66K	0.23%	$1.97M
Q3 asset management	16.47K	0.18%	$293.00K
Vance wealth	39.27K	0.13%	$306.27K
Sargent investment group	72.00K	0.11%	$561.60K
China universal asset management	82.47K	0.09%	$643.29K
Sectoral asset management	25.00K	0.08%	$195.00K

Top Buyers

Holder	Shares	% Assets	Change
Baker bros. advisors lp	23.22M	2.31%	23.22M
Price t rowe associates inc /md/	2.04M	0.00%	2.01M
Millennium management	1.94M	0.01%	1.94M
Vanguard group	8.82M	0.00%	1.55M
Balyasny asset management	1.01M	0.01%	1.01M

Top Sellers

Holder	Shares	% Assets	Change
State street	4.12M	0.00%	-3.99M
Blackrock	7.90M	0.00%	-1.92M
Anson funds management lp	-	-	-941.91K
Steward partners investment advisory	-	-	-606.50K
Bank of montreal /can/	-	-	-589.57K

New Positions

Holder	Shares	% Assets	Change	Value
Baker bros. advisors lp	23.22M	2.31%	23.22M	$181.13M
Millennium management	1.94M	0.01%	1.94M	$15.15M
Balyasny asset management	1.01M	0.01%	1.01M	$7.88M
Qvt financial lp	575.71K	0.42%	575.71K	$4.49M
Caption management	499.10K	0.06%	499.10K	$3.89M

Sold Out

Holder	Change
Citadel advisors	-5.00
Reuter james wealth management	-312.00
Pacer advisors	-944.00
Fny investment advisers	-1.10K
National bank of canada /fi/	-1.60K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	189	43.18%	84,448,625	17.02%	11	11.18%	115	79.69%	35	-23.91%
Jun 30, 2024	131	23.58%	72,166,501	45.37%	10	16.02%	64	10.34%	45	73.08%
Mar 31, 2024	106	9.28%	49,642,039	54.58%	8	37.82%	58	28.89%	26	36.84%
Dec 31, 2023	97	3.19%	32,113,817	-0.21%	4	21.63%	45	7.14%	19	-
Sep 30, 2023	94	-7.84%	32,181,292	-7.57%	4	5.44%	42	-28.81%	19	-9.52%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
SPDR® S&P Biotech ETF	3.55M	0.48%	-41.48K
Vanguard Total Stock Mkt Idx Inv	3.45M	0.47%	51.98K
Fidelity Select Biotechnology	3.04M	0.41%	-242.10K
Vanguard Small Cap Index	2.82M	0.38%	77.62K
iShares Russell 2000 ETF	2.48M	0.34%	-9.50K
Vanguard Institutional Extnd Mkt Idx Tr	2.13M	0.29%	68.75K
Vanguard Small Cap Value Index Inv	1.87M	0.25%	18.84K
Fidelity Growth Compy Commingled Pl S	939.26K	0.13%	9.60K
Fidelity Small Cap Index	893.65K	0.12%	3.61K
abrdn Healthcare Investors	852.28K	0.12%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 27, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$127.67K
Mar 27, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$74.20K
Mar 26, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$112.50K
Mar 27, 2024	Zanganeh Mahkam	Chief Executive Officer	Buy	$96.72K
Mar 26, 2024	Dhingra Ankur	Chief Financial Officer	Buy	$375.00K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	-
2024 Q3	-	-
2024 Q2	-	-
2024 Q1	5	-
2023 Q4	4	-

SMMT Ownership FAQ

Who Owns Summit Therapeutics?

Summit Therapeutics shareholders are primarily institutional investors at 11.62%, followed by 84.36% insiders and 4.02% retail investors. The average institutional ownership in Summit Therapeutics's industry, Biotech Stocks , is 109.70%, which Summit Therapeutics falls below.

Who owns the most shares of Summit Therapeutics?

Summit Therapeutics’s largest shareholders are Baker bros. advisors lp (23.22M shares, 3.31%), Vanguard group (8.82M shares, 1.26%), and Blackrock (7.9M shares, 1.13%). Together, they hold 5.69% of Summit Therapeutics’s total shares outstanding.

Does Blackrock own Summit Therapeutics?

Yes, BlackRock owns 1.13% of Summit Therapeutics, totaling 7.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 61.61M$. In the last quarter, BlackRock decreased its holdings by -1.925M shares, a -19.59% change.

Who is Summit Therapeutics’s biggest shareholder by percentage of total assets invested?

Baker bros. advisors lp is Summit Therapeutics’s biggest shareholder by percentage of total assets invested, with 2.31% of its assets in 23.22M Summit Therapeutics shares, valued at 181.13M$.

Who is the top mutual fund holder of Summit Therapeutics shares?

SPDR® S&P Biotech ETF is the top mutual fund holder of Summit Therapeutics shares, with 0.48% of its total shares outstanding invested in 3.55M Summit Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools